Pancreatic Cancer Research

ResearcherSun Yat-sen UniversityActive in the last 2 years

Chonghui Hu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-9305-9834; OpenAlex author ID A5026613368. Sources: OpenAlex.

Their work

Papers
12 (first author 6, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
31
Papers, trials and grants by year

2019: 1 paper · 2020: none · 2021: 1 paper · 2022: 4 papers · 2023: 2 papers · 2024: none · 2025: 2 papers · 2026: 2 papers

Papers 12

  1. circMTHFD1L-driven lipid metabolism in Cancer-associated fibroblasts confers oxaliplatin resistance in pancreatic cancer through O-GlcNAcylation-dependent chro… Co-author DOI 10.1016/j.canlet.2026.218863↗
  2. Lactylation-driven NSUN2-mediated RNA m5C modification promotes perineural invasion in pancreatic cancer. First author DOI 10.7150/thno.122294↗
  3. Glycolysis reprogramming in CAFs promotes oxaliplatin resistance in pancreatic cancer through circABCC4 mediated PKM2 nuclear translocation. First author DOI 10.1038/s41419-025-07431-4↗
  4. Cancer-Associated Fibroblasts Foster a High-Lactate Microenvironment to Drive Perineural Invasion in Pancreatic Cancer. First author DOI 10.1158/0008-5472.can-24-3173↗
  5. Extracellular vesicle-packaged circBIRC6 from cancer-associated fibroblasts induce platinum resistance via SUMOylation modulation in pancreatic cancer. Last author DOI 10.1186/s13046-023-02854-3↗
  6. HNF1A regulates oxaliplatin resistance in pancreatic cancer by targeting 53BP1. First author DOI 10.3892/ijo.2023.5493↗
  7. Corrigendum to "Macrophage-expressed CD51 promotes cancer stem cell properties via the TGF-β1/smad2/3 axis in pancreatic cancer" [Canc. Lett. 459(2019)204-215]. Co-author DOI 10.1016/j.canlet.2022.215897↗
  8. Cancer-associated fibroblast-induced lncRNA UPK1A-AS1 confers platinum resistance in pancreatic cancer via efficient double-strand break repair. Co-author DOI 10.1038/s41388-022-02253-6↗
  9. circFARP1 enables cancer-associated fibroblasts to promote gemcitabine resistance in pancreatic cancer via the LIF/STAT3 axis. Co-author DOI 10.1186/s12943-022-01501-3↗
  10. circCUL2 induces an inflammatory CAF phenotype in pancreatic ductal adenocarcinoma via the activation of the MyD88-dependent NF-κB signaling pathway. First author DOI 10.1186/s13046-021-02237-6↗
  11. A novel gene signature for prognosis prediction and chemotherapy response in patients with pancreatic cancer. First author DOI 10.18632/aging.202922↗
  12. Macrophage-expressed CD51 promotes cancer stem cell properties via the TGF-β1/smad2/3 axis in pancreatic cancer. Co-author DOI 10.1016/j.canlet.2019.06.005↗

Closest collaborators

The 25 strongest of 31 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Shangyou Zheng · 12 shared papers, 2019–2026 · strength 2.11
  2. Rihua He · 8 shared papers, 2022–2026 · strength 1.58
  3. Renpeng Xia · 5 shared papers, 2022–2023 · strength 0.78
  4. Zhihua Li · 5 shared papers, 2019–2026 · strength 0.76
  5. Tianhao Huang · 3 shared papers, 2025–2026 · strength 0.73
  6. Huimou Chen · 3 shared papers, 2025–2026 · strength 0.71
  7. Rufu Chen · 3 shared papers, 2025–2026 · strength 0.70
  8. Quanbo Zhou · 5 shared papers, 2019–2022 · strength 0.67
  9. Rufu Chen · 4 shared papers, 2021–2022 · strength 0.58
  10. Xiang Zhang · 3 shared papers, 2021–2023 · strength 0.49
  11. Zhiqiang Fu · 3 shared papers, 2019–2025 · strength 0.48
  12. Hongcao Lin · 3 shared papers, 2021–2022 · strength 0.45
  13. Yu Zhou · 2 shared papers, 2023–2026 · strength 0.41
  14. Guolin Li · 3 shared papers, 2019–2022 · strength 0.36
  15. Rufu Chen · 2 shared papers, 2022–2023 · strength 0.31
  16. Rufu Chen · 2 shared papers, 2019–2023 · strength 0.27
  17. Tian Qing · 1 shared paper, 2026 · strength 0.25
  18. Rufu Chen · 1 shared paper, 2026 · strength 0.25
  19. Yong Jiang · 1 shared paper, 2026 · strength 0.25
  20. Tingting Li · 1 shared paper, 2025 · strength 0.24
  21. Yu Zhou · 1 shared paper, 2025 · strength 0.22
  22. Yuan Yuan · 1 shared paper, 2025 · strength 0.22
  23. Chengyuan Hu · 1 shared paper, 2025 · strength 0.22
  24. Lusheng Wei · 2 shared papers, 2019–2022 · strength 0.22
  25. Bin Zhang · 2 shared papers, 2019–2022 · strength 0.22

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.